港股异动 | 三生制药(01530)跌超4% 与辉瑞许可协议生效 折让17.09%发新股筹7.85亿港元

智通财经
Jul 25, 2025

智通财经APP获悉,三生制药(01530)跌超4%,截至发稿,跌4.44%,报29.05港元,成交额5.25亿港元。

消息面上,三生制药公布,公司与辉瑞就PD-1/VEGF双特异性抗体(SSGJ-707)订立的许可协议之所有先决条件已达成,许可协议自7月24日起生效。同日,双方订立认购协议,向辉瑞发行3114.25万股,每股作价25.2055港元,较7月24日收报折让17.09%,总金额约7.85亿港元。完成后,辉瑞将持有公司股本1.28%。所得净额约80%用于丰富产品管线中的临床及临床前项目的全球研发布局,以及改善生产设施;余额拨作一般公司用途。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10